Steven Paul, M.D.

Steven Paul, M.D.

Chief Executive Officer and Chairman of the Board, Karuna Therapeutics

Dr. Steven Paul brings to BioXcel Therapeutics more than 35 years of neuroscience expertise and an extensive track record in CNS drug discovery and development. Dr. Paul is the Chief Executive Officer and Chairman of the Board of Karuna Therapeutics. He was formerly President and CEO of Voyager Therapeutics, a member of the Board of Directors and a venture partner at Third Rock Ventures. Preceding these appointments, Dr. Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including President of the Lilly Research Laboratories, and Vice President of discovery research and neuroscience research. As President of the Lilly Research Laboratories, he was responsible for the company’s overall R&D strategy, expanding its efforts in oncology and biotechnology, which resulted in a pipeline of approximately 70 new molecular entities. Dr. Paul currently serves on the Board of Directors of Sage Therapeutics and Alnylam Pharmaceuticals, and is a Chairman of the Board for the Foundation for the National Institutes of Health. Dr. Paul holds a B.A. in biology and psychology from Tulane University and an M.S. and M.D. from the Tulane University School of Medicine.

Sheila Gujrathi, M.D.

Sheila Gujrathi, M.D.

Co-Founder and Chief Executive Officer, Gossamer Bio

Dr. Gujrathi is the Co-Founder and Chief Executive Officer of Gossamer Bio. She most recently served as Chief Medical Officer of Receptos, an immunology-focused biotechnology company that was acquired by Celgene in August 2015 for $7.2 billion. At Receptos, she built the clinical development organization and advanced the pipeline of drug candidates, including Phase 3 programs in multiple sclerosis and ulcerative colitis. Previously, Dr. Gujrathi was Vice President of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb (BMS). There she led late-stage clinical development and supported regulatory filings for Orencia® and Nulojix®. She was also responsible for development of other assets in the BMS immunology clinical pipeline, and advised the strategies for discovery, early development and external business development within the immunoscience franchise. Prior to BMS, Dr. Gujrathi held roles in the immunology, tissue growth and repair clinical development groups at Genentech and served as the Avastin franchise team leader. Earlier in her career, she was a management consultant in McKinsey & Company’s healthcare practice. Dr. Gujrathi received her B.S. in biomedical Engineering and M.D. from Northwestern University in the Honors Program in Medical Education. She completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School, and additional fellowship training in Allergy/Immunology at UCSF and Stanford. She previously served on the Board of Directors of Ambrx, which was acquired in June 2015.